# A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

> **NCT06680947** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 225 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** 610
- **DRUG:** 610
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06680947
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2027-02
- **Final completion:** 2027-09
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680947, "A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06680947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*